TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06193889: KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Sponsor: Kyverna Therapeutics · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 66 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,118,808

Rescue Site Savings

+$2,065,704

Unlock Full NCT06193889 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06193889 Rescue Dossier →